Suppr超能文献

手术切除与 CT 引导下经皮消融治疗 I 期非小细胞肺癌(NSCLC)的生存结局:系统评价和荟萃分析。

Survival outcomes for surgical resection versus CT-guided percutaneous ablation for stage I non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.

机构信息

Department of Radiology, Concord Repatriation General Hospital, Concord, NSW, 2137, Australia.

Concord Hospital Clinical Medical School, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia.

出版信息

Eur Radiol. 2021 Jul;31(7):5421-5433. doi: 10.1007/s00330-020-07634-7. Epub 2021 Jan 15.

Abstract

OBJECTIVE

Multiple cohort studies have compared surgical resection with CT-guided percutaneous ablation for patients with stage 1 non-small cell lung cancer (NSCLC); however, the results have been heterogeneous. This systematic review and meta-analysis aims to compare surgery with ablation for stage 1 NSCLC.

METHOD

A search of five databases was performed from inception to 5 July 2020. Studies were included if overall survival (OS), cancer-specific survival (CSS), and/or disease-free survival (DFS) were compared between patients treated with surgical resection versus ablation (radiofrequency ablation (RFA) or microwave ablation (MWA)) for stage 1 NSCLC. Pooled odds ratios (OR) were calculated.

RESULTS

A total of eight studies were included (total 792 patients: 460 resection and 332 ablation). There were no significant differences in 1- to 5-year OS or CSS between surgery versus ablation. There were significantly better 1- and 2-year DFS for surgery over ablation (OR 2.22, 95% CI 1.14-4.34; OR 2.60, 95% CI 1.21-5.57 respectively), but not 3- to 5-year DFS. Subgroup analysis demonstrated no significant OS difference between lobectomy and MWA, but there were significantly better 1- and 2-year OS with sublobar resection (wedge resection or segmentectomy) versus RFA (OR 2.85, 95% CI 1.33-6.10; OR 4.54, 95% CI 2.51-8.21, respectively). In the two studies which only included patients with stage 1A NSCLC, pooled outcomes demonstrated no significant differences in 1- to 3-year OS or DFS between surgery versus ablation.

CONCLUSION

Surgical resection of stage 1 NSCLC remains the optimal choice. However, for non-surgical patients with stage 1A, ablation offers promising DFS, CSS, and OS. Future prospective randomized controlled trials are warranted.

KEY POINTS

• Surgical resection of stage 1 NSCLC remains the optimal choice. • In patients with stage 1A NSCLC who are not surgical candidates, CT-guided microwave or radiofrequency ablation may be an alternative which offers promising disease-free survival and overall survival.

摘要

目的

多项队列研究比较了手术切除与 CT 引导下经皮消融治疗Ⅰ期非小细胞肺癌(NSCLC)患者的效果;然而,结果存在异质性。本系统评价和荟萃分析旨在比较手术与消融治疗Ⅰ期 NSCLC 的效果。

方法

从建库到 2020 年 7 月 5 日,对五个数据库进行了检索。如果治疗Ⅰ期 NSCLC 的患者接受手术切除与消融(射频消融(RFA)或微波消融(MWA))治疗后,总体生存率(OS)、癌症特异性生存率(CSS)和/或无病生存率(DFS)进行了比较,则纳入研究。计算汇总优势比(OR)。

结果

共纳入 8 项研究(共 792 例患者:460 例手术切除,332 例消融)。手术与消融在 1 至 5 年 OS 或 CSS 方面无显著差异。手术组 1 年和 2 年 DFS 明显优于消融组(OR 2.22,95%CI 1.14-4.34;OR 2.60,95%CI 1.21-5.57),但 3 年至 5 年 DFS 无显著差异。亚组分析显示,肺叶切除术与 MWA 之间 OS 无显著差异,但亚肺叶切除术(楔形切除术或节段切除术)与 RFA 相比,1 年和 2 年 OS 明显更好(OR 2.85,95%CI 1.33-6.10;OR 4.54,95%CI 2.51-8.21)。在仅纳入ⅠA 期 NSCLC 患者的两项研究中,汇总结果显示手术与消融在 1 年至 3 年 OS 或 DFS 方面无显著差异。

结论

手术切除Ⅰ期 NSCLC 仍然是最佳选择。然而,对于不能手术的ⅠA 期患者,CT 引导下微波或射频消融可能是一种有前途的治疗选择,能够提供良好的无病生存率和总生存率。未来需要前瞻性随机对照试验。

关键点

• 手术切除Ⅰ期 NSCLC 仍然是最佳选择。

• 对于不能手术的ⅠA 期 NSCLC 患者,CT 引导下微波或射频消融可能是一种有前途的治疗选择,可提供良好的无病生存率和总生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验